• SPX
  • $5,621.62
  • -0.2 %
  • -$11.47
  • DJI
  • $41,568.91
  • -0.13 %
  • -$53.18
  • N225
  • $36,203.22
  • -1.03 %
  • -$378.54
  • FTSE
  • $8,309.86
  • 0.38 %
  • $31.42
  • IXIC
  • $17,595.43
  • 0.02 %
  • $3.31
Akero Therapeutics, Inc. (AKRO) Stock Price, News & Analysis

Akero Therapeutics, Inc. (AKRO) Stock Price, News & Analysis

Currency in USD Disclaimer

$26.74

-$0.03

(-0.11%)

Day's range
$26.52
Day's range
$27.65
50-day range
$22.01
Day's range
$29.12
  • Country: US
  • ISIN: US00973Y1082
52 wk range
$11.25
Day's range
$53
  • CEO: Dr. Andrew Cheng M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 15.90
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (AKRO)
  • Company Akero Therapeutics, Inc.
  • Price $26.74
  • Changes Percentage (-0.11%)
  • Change -$0.03
  • Day Low $26.52
  • Day High $27.65
  • Year High $53.00

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/10/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $45.00
  • High Stock Price Target $56.00
  • Low Stock Price Target $38.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.24
  • Trailing P/E Ratio -7.1
  • Forward P/E Ratio -7.1
  • P/E Growth -7.1
  • Net Income $-151,759,000

Income Statement

Quarterly

Annual

Latest News of AKRO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.